Senior Leadership

高层领导

• 批准号: 7696564
• 负责人: KEVIN J. CULLEN
• 金额: $ 8.56万
• 依托单位: UNIVERSITY OF MARYLAND BALTIMORE
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-08-08 至 2011-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7696564
• 关键词: Accounting; Administrator; Advisory Committees; American Cancer Society; Antineoplastic Agents; Appointment; Area; Baltimore; Basic Science; Biopolymers; Bone Marrow Transplantation; Boston; Budgets; Cancer Center; Cancer Center Support Grant; Caring; Cigarette; Clinic; Clinical; Clinical Research; Clinical Services; Clinical Trials; Clinical Trials Design; Collaborations; Communication; Country; Development; Developmental Therapeutics Program; Division of Cancer Treatment and Diagnosis; Doctor of Medicine; Doctor of Philosophy; Drug effect disorder; Endowment; Ethics; Evaluation; Excision; Extramural Activities; Extramural Research Program; Faculty; Federal Government; Fellowship; Funding; Future; Goals; Grant; Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma; Health Sciences; Hematology; Hormone Responsive; Hospitals; Housing; Infusion procedures; Inpatients; Institutes; Internal Medicine; Israel; Laboratories; Laboratory Research; Leadership; Legislative Liaison; London; Malignant Neoplasms; Maryland; Medical; Medical Oncology; Medical center; Medicine; Modification; Molecular; Morbidity - disease rate; National Cancer Institute; National Institute on Alcohol Abuse and Alcoholism; Operations Research; Operative Surgical Procedures; Otolaryngology; Outpatients; Patient Care; Phase; Philanthropic Fund; Positioning Attribute; Preclinical Drug Development; Principal Investigator; Process; Prognostic Marker; Radiation Oncology; Radiation Therapy Oncology Group; Rapid Access to Intervention Development; Recruitment Activity; Research; Research Activity; Research Personnel; Research Support; Residencies; Resistance; Resources; Role; Series; Services; Site Visit; Standards of Weights and Measures; State Government; Strategic Planning; Structure; Study Section; System; Texas; Therapeutic Agents; Time; Training; Translational Research; United States National Institutes of Health; Universities; Vision; Visit; Wages; Week; anticancer research; authority; base; cancer care; cancer research center director; cancer therapy; computerized; design; drug development; drug discovery; experience; falls; health administration; improved; interest; laboratory facility; medical schools; member; mortality; multidisciplinary; oncology; pre-clinical; professor; programs; ranpirnase; repaired; woman health professional

In 2002, the University of Maryland Marlene and Stewart Greenebaum Cancer Center (UMGCC) senior leadership team consisted of Sanford Stass, M.D., director; Barry Meisenberg, M.D., associate director for Clinical Research; Amy Fulton, Ph.D., associate director for Basic Science; and Mr. Mark Kochevar, associate director for Administration. Since 2003 there has been a complete reorganization of UMGCC, with recruitment of a new cadre of senior leaders. This change has been part of an overall restructuring at UMGCC, resulting in three full research programs and two developing recruitment programs, four full shared services and four developing shared services, and 41 new investigators. With these changes, there has been a dramatic increase in research activity and funding support. In 2003, UMGCC recruited Dr. Alan Tomkinson from the University of Texas Health Science Center at San Antonio to serve as the new associate director of Basic Science. He held a similar cancer center leadership position in Texas. Dr. Tomkinson is an internationally recognized expert in the field of DMA repair, and he oversees the basic research activities at UMGCC. Dr. Amy Fulton has moved to take on the leadership for the newly formed Hormone Responsive Cancers Program. In January 2004, Dr. Donald Wilson, dean of the University of Maryland School of Medicine (UMSOM), recruited Dr. Kevin Cullen as the new director of UMGCC. Dr. Cullen was previously professor of Medicine and Otolaryngology at the Lombardi Cancer Center of Georgetown University. He was acting director of that cancer center from 2000 to 2002 and was responsible for the successful recompetition of its P30 CCSG in 2002. Dr. Cullen's clinical and research interests are the molecular mechanisms of drug action and resistance in head and neck cancer. Drawing on his previous experience at the Lombardi Cancer Center, Dr. Cullen undertook the extensive reorganization of UMGCC after his arrival in January 2004. The reorganized structure of UMGCC is evident throughout this application. Dr. Cullen recruited Dr. Edward Sausville as associate director for Clinical Research in the summer of 2004. Dr. Sausville had previously been associate director of the Division of Cancer Treatment and Diagnosis of the National Cancer Institute (NCI), and in that capacity led NCI's Developmental Therapeutics Program. This role managed the preclinical drug discovery and development process for NCI-originated therapeutic agents. In addition, Dr. Sausville designed, implemented, and had administrative oversight of NCI's Rapid Access to Intervention Development Program and Rapid Access to NCI Discovery Program, which extended NCIcontract- based preclinical drug development resources to extramural investigators. Dr. Sausville is an internationally recognized authority on cancer drug development and early-phase clinical trial design. Since his arrival at UMGCC, Dr. Sausville has undertaken an extensive revision of UMGCC's clinical research apparatus. Dr. Meisenberg, the previous associate director for Clinical Research, is now chief of the division of Hematology/Oncology and continues his clinical research activities in bone marrow transplantation and other areas. Dr. Cullen also appointed Dr. Nicholas Ambulos director of Shared Services in 2004. Dr. Ambulos jointly serves as the director of the Biopolymer Shared Service, which is used extensively by investigators at UMGCC and UMSOM. Since 2004 he has overseen a reorganization of the shared services, including implementation of computerized order-entry and accounting systems, uniform governance for shared services, as well as strategic planning for implementation of new shared services and modification of existing ones. In 2005, Dr. Cullen appointed Dr. Mohan Suntharalingam to the newly created position of associate director for Clinical Services. Dr. Suntharalingam is vice chair of the Department of Radiation Oncology and is principal investigator (PI) for the University of Maryland's (UM's) Radiation Therapy Oncology Group (RTOG) grant. His clinical and research interests are aerodigestive cancers, and he has been the PI on numerous investigatorinitiated trials in head and neck cancer and other aerodigestive malignancies. Dr. Suntharalingam has administrative oversight of UMGCC's multidisciplinary clinical programs and has been instrumental in designing and implementing multidisciplinary clinics to facilitate patient care and clinical research. In 2006, Dr. Cullen recruited Mr. Stephen W. Long as the new associate director for Administration. Mr. Long has more than 37 years of experience in health administration in the Federal Government. He concluded a 28- year tenure in the senior administrative ranks of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), serving as the executive officer of NIAAA for 8 years prior to his move to UMGCC. Mr. Long had administrative responsibility for both the intra- and extramural research programs of the NIAAA and also was a member of leadership at the National Institutes of Health (NIH), serving and/or chairing critical NIH committees on Ethics, the Office of Resource Services Council, and Senior Executive Service Search Committees, to mention a few of his responsibilities. Since his arrival at UMGCC, he has begun reorganizing the administrative structure of UMGCC, as well as its research operations. He has also been responsible for the oversight of significant expansion of UMGCC's laboratory facilities, and has also planned for extensive renovation of clinical and clinical research support facilities. Dr. Cullen recruited Ms. Laurene Mead as the senior administrator for Clinical Services in 2007. This newly created position provides administrative oversight of the outpatient and inpatient clinical operations at UMGCC. Ms. Mead previously held a similar leadership position at Greater Baltimore Medical Center, where she had oversight of cancer services, as well as women's health and professional services. Her primary responsibilities include the outpatient operations of UMGCC, which handles more than 24,000 outpatient visits and 12,000 infusion visits per year. UMGCC's leadership meets three times per month with program leaders as the Cancer Center Leadership Group (CCLG). This group is responsible for strategic planning, oversight of research and clinical operations, and approval of new faculty and senior-staff recruitments. Dr. Cullen meets separately each week with the senior administrative group, including Mr. Long; Ms. Mead; Susan Myers, director of Finance; Barry Meisenberg, chief of the Division of Hematology/Oncology; and Dr. Mohan Suntharalingam. These weekly administrative meetings deal with pressing operational issues and routine review of the financial status of UMGCC. As noted throughout this application, the reorganization of the senior leadership at UMGCC has been accompanied by a dramatic increase in the clinical research activities during the past 5 years. Since 2002 clinical activities have increased dramatically, while funding for cancer research has risen from $25.6 million annually to more than $47.1 million annually. Senior leadership has been responsible for developing and executing long-term vision and strategic planning for UMGCC, facilitating the NCI goal of reducing morbidity and mortality from cancer. In the last 5 years, UMGCC has emerged as a significant regional and national resource. It has become a major regional referral center for multidisciplinary cancer care, clinical trials, and specialized cancer treatment services. More important, UMGCC's investigators have changed the landscape of cancer treatment beyond the region, developing significantly improved cancer therapies that are now standard care worldwide

2002年，马里兰大学Marlene和Stewart Greenebaum癌症中心（UMGCC）高级 领导团队由主任 Sanford Stass, M.D. 组成； Barry Meisenberg，医学博士，副主任 临床研究； Amy Fulton 博士，基础科学副主任；和 Mark Kochevar 先生，合伙人 行政总监。自 2003 年以来，UMGCC 进行了彻底重组，并招募了 形成了新的高级领导干部队伍。这一变化是 UMGCC 整体重组的一部分，导致 三个完整的研究计划和两个正在开发的招聘计划、四个完整的共享服务和四个 开发共享服务，以及 41 名新调查员。随着这些变化，发生了戏剧性的变化 增加研究活动和资金支持。 2003年，UMGCC聘请了来自圣路易斯德克萨斯大学健康科学中心的Alan Tomkinson博士 安东尼奥担任基础科学的新副主任。他担任过类似的癌症中心领导职务 在德克萨斯州的地位。 Tomkinson 博士是国际公认的 DMA 修复领域专家，他 监督 UMGCC 的基础研究活动。艾米·富尔顿 (Amy Fulton) 博士已开始担任该项目的领导职务 新成立的激素反应性癌症计划。 2004年1月，马里兰大学医学院（UMSOM）院长唐纳德·威尔逊博士， 聘请Kevin Cullen博士为UMGCC新任主任。卡伦博士曾是医学教授和 乔治城大学隆巴迪癌症中心的耳鼻喉科。他是那个癌症的代理导演 2000 年至 2002 年期间在中心工作，并负责 2002 年 P30 CCSG 的成功复赛。 卡伦的临床和研究兴趣是头部药物作用和耐药性的分子机制 和颈部癌症。卡伦博士借鉴了他之前在隆巴迪癌症中心的经验， 2004 年 1 月他到任后，UMGCC 进行了大规模重组。UMGCC 重组后的结构 在整个申请中都是显而易见的。 2004 年夏天，Cullen 博士聘请 Edward Sausville 博士担任临床研究副主任。 Sausville 博士此前曾担任癌症治疗和诊断部门的副主任 美国国家癌症研究所 (NCI)，并以此身份领导 NCI 的发展治疗计划。这个角色 管理 NCI 原创治疗药物的临床前药物发现和开发过程。在 此外，Sausville 博士还设计、实施了 NCI 的快速访问并对其进行行政监督。 干预开发计划和快速进入 NCI 发现计划，该计划延长了 NCI 合同- 为校外研究人员提供临床前药物开发资源。索斯维尔博士是 国际公认的癌症药物开发和早期临床试验设计权威。自从他的 抵达 UMGCC 后，Sausville 博士对 UMGCC 的临床研究进行了广泛的修订 设备。 Meisenberg 博士，前临床研究副主任，现任临床研究部主任 血液学/肿瘤学并继续他在骨髓移植和其他方面的临床研究活动 地区。 Cullen 博士还于 2004 年任命 Nicholas Ambulos 博士为共享服务总监。Ambulos 博士共同担任 担任生物聚合物共享服务的主管，该服务被 UMGCC 的研究人员广泛使用 和UMSOM。自 2004 年以来，他负责监督共享服务的重组，包括实施 计算机化订单输入和会计系统、共享服务的统一治理以及 实施新共享服务和修改现有共享服务的战略规划。 2005 年，Cullen 博士任命 Mohan Suntharalingam 博士担任新设立的副主任职位 临床服务。 Suntharalingam 博士是放射肿瘤科副主任兼主任 马里兰大学 (UM) 放射治疗肿瘤学组 (RTOG) 资助的研究员 (PI)。他的 临床和研究兴趣是呼吸消化癌，他是许多研究者发起的 PI 头颈癌和其他呼吸消化恶性肿瘤的试验。 Suntharalingam 博士有 对 UMGCC 多学科临床项目的行政监督，并在以下方面发挥了重要作用： 设计和实施多学科诊所以促进患者护理和临床研究。 2006 年，Cullen 博士聘请 Stephen W. Long 先生担任新的行政副主任。龙先生 在联邦政府卫生管理方面拥有超过 37 年的经验。他总结了28- 在国家酒精滥用和酒精中毒研究所担任高级行政职务一年 (NIAAA)，在调到 UMGCC 之前担任 NIAAA 执行官 8 年。龙先生有 NIAAA 的校内和校外研究项目的行政责任，也是 美国国立卫生研究院 (NIH) 的领导成员，服务和/或主持重要的 NIH 委员会 道德委员会、资源服务理事会办公室和高级行政服务搜寻委员会， 提及他的一些职责。自从他到达 UMGCC 以来，他就开始重组行政部门。 UMGCC 的结构及其研究运作。他还负责监督 显着扩大 UMGCC 的实验室设施，并计划对临床实验室进行大规模翻新 和临床研究支持设施。 2007 年，Cullen 医生聘请 Laurene Mead 女士担任临床服务高级管理人员。 创建的职位负责对 UMGCC 的门诊和住院临床操作进行行政监督。 米德女士此前曾在大巴尔的摩医疗中心担任过类似的领导职务，她曾在那里担任过 监督癌症服务以及妇女健康和专业服务。她的主要职责 包括 UMGCC 的门诊业务，处理超过 24,000 名门诊患者和 12,000 名患者 每年输液次数。 UMGCC 的领导层每月与癌症中心领导层的项目负责人会面 3 次 集团（CCLG）。该小组负责战略规划、研究和临床操作的监督， 并批准新教师和高级职员的招聘。卡伦博士每周单独与 高级管理团队，包括龙先生；米德女士；苏珊·迈尔斯，财务总监；巴里 Meisenberg，血液学/肿瘤科主任；和莫汉·桑塔拉林加姆博士。这些每周 行政会议处理紧迫的运营问题并对财务状况进行例行审查 UMGC。 正如本申请中所指出的，UMGCC 高级领导层的重组已经 伴随着过去5年临床研究活动的急剧增加。自2002年起 临床活动急剧增加，癌症研究经费从 2560 万美元增加到 每年超过 4710 万美元。高层领导一直负责开发和 执行 UMGCC 的长期愿景和战略规划，促进 NCI 降低发病率的目标 和癌症死亡率。在过去 5 年里，UMGCC 已成为重要的地区和国家组织 资源。它已成为多学科癌症护理、临床试验和治疗的主要区域转诊中心。 专门的癌症治疗服务。更重要的是，UMGCC 的调查人员改变了现状 超越该地区的癌症治疗，开发出显着改进的癌症疗法，这些疗法现已成为标准 全球护理